Presilium Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Presilium Private Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$954K	Buy	2,137 +10	+0.5%	+$4.66K	0.17%	35
2025 Q4	$964K	Buy	2,127 +3	+0.1%	+$1.29K	0.18%	36
2025 Q3	$832K	Hold	2,124	–	–	0.16%	38
2025 Q2	$946K	Hold	2,124	–	–	0.19%	33
2025 Q1	$1.03M	Hold	2,124	–	–	0.23%	32
2024 Q4	$855K	Sell	2,124 -6	-0.3%	-$2.78K	0.2%	39
2024 Q3	$991K	Hold	2,130	–	–	0.23%	35
2024 Q2	$998K	Buy	+2,130	New	+$925K	0.25%	33

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Presilium Private Wealth's VRTX Position: Q1 2026 in Review

Presilium Private Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 0.47% in Q1 2026, buying an estimated $4.66K and bringing the position to 2,137 shares worth $954K. The position accounts for 0.17% of the portfolio, ranked #35.

Presilium Private Wealth first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.03M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Presilium Private Wealth held 2,137 shares of Vertex Pharmaceuticals worth $954K as of Q1 2026.
Presilium Private Wealth bought 10 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.66K.
Vertex Pharmaceuticals made up 0.17% of Presilium Private Wealth's portfolio in Q1 2026, its #35 holding.
Presilium Private Wealth first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Presilium Private Wealth's Vertex Pharmaceuticals position peaked at $1.03M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Presilium Private Wealth's 13F filing for Q1 2026, filed 17 Apr 2026.